Back to Treatments

Treatment

Brentuximab vedotin + AVD (Doxorubicin, Vinblastine, Dacarbazine)

1
Conditions
19
Trials
8,000
Participants
30%
Average Safety

Condition Evidence

Hodgkin lymphoma

19 trials · 8,000 participants

88% effectiveness · 30% safety
Brentuximab vedotin + AVD (Doxorubicin, Vinblastine, Dacarbazine) | DFDA